120 related articles for article (PubMed ID: 6295896)
21. Effect of thromboxane synthetase inhibitors on platelet function: enhancement by inhibition of phosphodiesterase.
Smith JB
Thromb Res; 1982 Nov; 28(4):477-85. PubMed ID: 6891843
[TBL] [Abstract][Full Text] [Related]
22. Inhibitors of platelet signal transduction as anti-aggregatory drugs.
Geiger J
Expert Opin Investig Drugs; 2001 May; 10(5):865-90. PubMed ID: 11322863
[TBL] [Abstract][Full Text] [Related]
23. Effects of prostacyclin analogue (carbacyclin) on the interaction of platelets with different collagen substrates. Inhibition of cAMP increase by collagens type I, III, and IV.
Mazurov AV; Misselwitz F; Hoffman U; Leytin VL; Repin VS
Prostaglandins; 1988 Jan; 35(1):51-65. PubMed ID: 2836888
[TBL] [Abstract][Full Text] [Related]
24. The effect of phospholipase inhibitor mepacrine on platelet aggregation, the platelet release reaction and fibrinogen binding to the platelet surface.
Winocour PD; Kinlough-Rathbone RL; Mustard JF
Thromb Haemost; 1981 Jun; 45(3):257-62. PubMed ID: 7281105
[TBL] [Abstract][Full Text] [Related]
25. Structure-function relationships in the activation of platelet thrombin receptors by receptor-derived peptides.
Vassallo RR; Kieber-Emmons T; Cichowski K; Brass LF
J Biol Chem; 1992 Mar; 267(9):6081-5. PubMed ID: 1313429
[TBL] [Abstract][Full Text] [Related]
26. The metalloprotease, NN-PF3 from Naja naja venom inhibits platelet aggregation primarily by affecting α2β1 integrin.
Kumar MS; Girish KS; Vishwanath BS; Kemparaju K
Ann Hematol; 2011 May; 90(5):569-77. PubMed ID: 20957364
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory effects of ZK 36374, a stable prostacyclin analogue, on adhesion of rabbit platelets to damaged aorta and serotonin release by adherent platelets.
Menys VC; Davies JA
Clin Sci (Lond); 1983 Aug; 65(2):149-53. PubMed ID: 6190604
[TBL] [Abstract][Full Text] [Related]
28. 2-[3-[2-(4,5-Diphenyl-2-oxazolyl) ethyl] phenoxy] acetic acid (BMY 42393): a new, structurally-novel prostacyclin partial agonist: 1). Inhibition of platelet aggregation and mechanism of action.
Seiler SM; Brassard CL; Federici ME; Buchanan JO; Zavoico GB; Fleming JS; Meanwell NA
Thromb Res; 1994 Apr; 74(2):115-23. PubMed ID: 8029812
[TBL] [Abstract][Full Text] [Related]
29. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
Hoet B; Arnout J; Deckmyn H; Vermylen J
Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
[TBL] [Abstract][Full Text] [Related]
30. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
[TBL] [Abstract][Full Text] [Related]
31. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
[TBL] [Abstract][Full Text] [Related]
32. Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production.
Jeng JH; Wu HL; Lin BR; Lan WH; Chang HH; Ho YS; Lee PH; Wang YJ; Wang JS; Chen YJ; Chang MC
Atherosclerosis; 2007 Apr; 191(2):250-8. PubMed ID: 16797553
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of ADP-induced responses in human platelets by agents elevating the cyclic AMP level: comparison of aggregation and shape change.
Steen VM; Holmsen H
Thromb Haemost; 1984 Dec; 52(3):333-5. PubMed ID: 6099615
[TBL] [Abstract][Full Text] [Related]
34. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors.
Gorman RR
Adv Prostaglandin Thromboxane Res; 1980; 6():417-25. PubMed ID: 6247892
[No Abstract] [Full Text] [Related]
35. Dicentrine, a novel antiplatelet agent inhibiting thromboxane formation and increasing the cyclic AMP level of rabbit platelets.
Yu SM; Chen CC; Ko FN; Huang YL; Huang TF; Teng CM
Biochem Pharmacol; 1992 Jan; 43(2):323-9. PubMed ID: 1310852
[TBL] [Abstract][Full Text] [Related]
36. Pharmacology of platelet-affecting drugs.
Packham MA; Mustard JF
Circulation; 1980 Dec; 62(6 Pt 2):V26-41. PubMed ID: 6254690
[No Abstract] [Full Text] [Related]
37. Effect of the calcium-entry blocking agent nifedipine on activation of human platelets and comparison with verapamil.
Han P; Boatwright C; Ardlie NG
Thromb Haemost; 1983 Aug; 50(2):513-7. PubMed ID: 6314581
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of platelet aggregation by chlorogenic acid via cAMP and cGMP-dependent manner.
Cho HJ; Kang HJ; Kim YJ; Lee DH; Kwon HW; Kim YY; Park HJ
Blood Coagul Fibrinolysis; 2012 Oct; 23(7):629-35. PubMed ID: 22885765
[TBL] [Abstract][Full Text] [Related]
39. PGE(2) reverses G(s)-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-G(s)-mediated inhibition of platelet aggregation by interaction with EP4 receptors.
Glenn JR; White AE; Iyu D; Heptinstall S
Platelets; 2012; 23(5):344-51. PubMed ID: 22436052
[TBL] [Abstract][Full Text] [Related]
40. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.
Aiken JW; Shebuski RJ; Miller OV; Gorman RR
J Pharmacol Exp Ther; 1981 Nov; 219(2):299-308. PubMed ID: 6270303
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
